Abstract:Background: An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear.
Objective: To assess the effectiveness of tralokinumab on different anatomical sites and clinical signs of AD.
Methods: This study included 129 moderate-to-severe AD patients treated with tralokinumab for 36 weeks. Eczema Area and Severity Index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification) at weeks 0, 4, 12, 24, and 36.
Results: Tralokinumab consistently reduced EASI scores on 4 anatomical sites and 4 clinical signs. The magnitude of decreasing EASI appeared highest on lower limbs while the achievement rates of EASI 75 at week 36 on 4 anatomical sites were mostly similar (72.6–77.6%). The magnitude of decreasing EASI and achieving EASI 75 or 100 appeared highest for excoriation, and the rates of EASI 75 at week 36 for erythema, excoriation, lichenification and edema/papulation were 71.1%, 69.4%, 68.4%, and 60.5%, respectively.
Conclusions: Tralokinumab reduced EASI scores across various anatomical sites and clinical signs in moderate-to-severe AD patients. These findings suggest that tralokinumab may be widely useful for diverse skin manifestations of AD.
Get full access to this article
View all access options for this article.
References
1.
NomuraT, SandilandsA, AkiyamaM, et al.Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119(2):434–440.
2.
HondaT, KabashimaK. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020; 145(4):1136–1137.
3.
HaginoT, SaekiH, KandaN. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022; 49(11):1158–1167.
4.
SilverbergJI. Atopic dermatitis in adults. Med Clin North Am. 2020; 104(1):157–176.
KamataM, TadaY. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023; 3(3):100195.
7.
NakashimaC, YanagiharaS, OtsukaA. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71(1):40–46.
8.
BieberT. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020; 75(1):54–62.
9.
Marbach-BreitrückE, KalledatA, HeydeckD, et al.Atopic patients show increased Interleukin 4 plasma levels but the degree of elevation is not sufficient to upregulate Interleukin-4-sensitive genes. Skin Pharmacol Physiol. 2019; 32(4):192–200.
10.
SzegediK, LutterR, ResPC, et al.Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015; 29(11):2136–2144.
11.
TubauC, PuigL. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021; 17(1):15–25.
12.
TsoiLC, RodriguezE, DegenhardtF, et al.Atopic dermatitis is an IL-13-Dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019; 139(7):1480–1489.
13.
PopovicB, BreedJ, ReesDG, et al.Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017; 429(2):208–219.
14.
WollenbergA, BlauveltA, Guttman-YasskyE, et al.ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184(3):437–449.
15.
SilverbergJI, TothD, BieberT, et al.ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184(3):450–463.
16.
PallerAS, FlohrC, CorkM, et al.Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023; 159(6):596–605.
17.
SilverbergJI, AdamDN, ZirwasM, et al.Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: An ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022; 23(4):547–559.
18.
GutermuthJ, PinkAE, WormM, et al.Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: A placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022; 186(3):440–452.
19.
SchlösserAR, ShareefM, OlydamJ, et al.Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023; 48(5):510–517.
20.
García CastroR, Heras MendazaF, Santiago Sánchez-MateosDI, et al.First short-term effectiveness and security data of tralokinumab in severe atopic Dermatitis® in real clinical practice. Dermatitis. 2024; 35(3):301–303.
21.
PolaskeyMT, FakhraieS, DaftaryK, et al.An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab. Dermatitis. 2024.
22.
PotestioL, PatrunoC, NapolitanoM. Efficacy and safety of tralokinumab in real life: Possible predictive rapid response factors. Dermatitis. 2024; 35(S1):S77–S80.
23.
HaginoT, OndaM, SaekiH, et al.Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan. Eur J Dermatol. 2024; 34(5):525–532.
24.
HaginoT, OndaM, SaekiH, et al.Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study. Dermatitis. 2024.
25.
SaekiH, OhyaY, FurutaJ, et al.Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022; 71(4):448–458.
26.
HaginoT, SaekiH, FujimotoE, et al.The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023; 34(1):2212095.
27.
HaginoT, SaekiH, FujimotoE, et al.Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023; 50(7):869–879.
28.
MurotaH, YamagaK, OnoE, et al.Sweat in the pathogenesis of atopic dermatitis. Allergol Int. 2018; 67(4):455–459.
29.
CoullNA, WestAM, HodderSG, et al.Body mapping of regional sweat distribution in young and older males. Eur J Appl Physiol. 2021; 121(1):109–125.
30.
BlauveltA, RosmarinD, BieberT, et al.Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: Data from phase III clinical trials. Br J Dermatol. 2019; 181(1):196–197.
31.
JarosJ, HendricksAJ, ShiVY, et al.A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020; 31(3):169–177.
32.
HaginoT, YoshidaM, HamadaR, et al.Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023; 50(12):1576–1584.
33.
LicataG, GambardellaA, TancrediV, et al.Face atopic dermatitis resistant to dupilumab: A case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022; 36(2):e150–e152.
